RegeneRx Completes Enrollment And Dosing Of Phase IA Safety Trial For Potential Heart Drug - First Injectable Use Of RGN-352 Tested In Humans |
Fluoxetine: useful modern medicine.uses of Fluoxetine Fluoxetine is a selective serotonin reuptake inhibitor ( SSRI ) used to treat depression, anxiety disorders ( panic attacks ) , obsessive-compulsive disorder ( OCD ) , a certain eating disorder ( bulimia ) , and a severe form of premenstrual syndrome ( premenstrual dysphoric disorder ) . how to use of Fluoxetine Read Medication Guide provided by your pharmacist before you start using Fluoxetine and each time we get a refill. If we have any questions, consult your doctor or pharmacist. other used of Fluoxetine This section contains uses of Fluoxetine that aren't listed in the approved professional labeling for drug but that may be prescribed by your health care professional. Use Fluoxetine for a condition that is listed in this section only if it has been so prescribed by your health care professional. side effects of Fluoxetine See also Warning section. precautions of Fluoxetine Before taking Fluoxetine, tell your doctor or pharmacist if you're allergic to it; or if we have any other allergies. interactions of Fluoxetine Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring we for them. Don't start, stop, or change dosage of any medicine before checking with your doctor or pharmacist first. FDA approved Fluoxetine |
RegeneRx Completes Enrollment And Dosing Of Phase IA Safety Trial For Potential Heart Drug - First Injectable Use Of RGN-352 Tested In HumansRegenerx Biopharmaceuticals, Inc. announced today that it has completed enrollment and dosing of 40 healthy subjects for its Phase IA clinical trial testing RGN-352, an injectable formulation of Tβ4 for potential use in treating acute myocardial infarction patients ( AMI or heart attack ) . The trial includes four groups of ten subjects each to assess safety of escalating doses of RGN-352 injected into the blood stream. To date, there have been no significant drug-related adverse events. A final analysis and report will be completed after 28 days of follow-up of last subject. RegeneRx expects to initiate second part of Phase I with a Phase IB trial in the 3rd quarter 2008 after submitting a IA report to FDA. The IB trial design is similar to IA; however, the 40 subjects will be dosed once daily for 14 days, rather than given only a single dose, and will undergo a 28-day and a 6-month follow-up. " We've reached an important milestone with completion of enrollment and dosing of Phase IA trial. RGN-352 appears to be safe in single doses at low, medium, and high concentrations. This is an exciting and positive step as we prepare for IB phase of trial. This trial is intended to provide safety data for Phase II clinical trials that are being planned to evaluate RGN-352 for treatment of patients immediately after an AMI and also to support other potential uses of RGN-352 in medical indications where short-term systemic administration of the drug candidate may be warranted, " stated J. J. Finkelstein, RegeneRx's president and chief executive officer. About RegeneRx Biopharmaceuticals, Inc. RegeneRx is focused on discovery and development of novel peptides to accelerate tissue and organ repair. Currently, RegeneRx is developing three product candidates, RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic, and cardiovascular tissue repair, respectively. These product candidates are based on Tβ4, a 43-amino acid, naturally occurring peptide, in part, under an exclusive world-wide license from the National Institutes of Health. RegeneRx holds over 60 world-wide patents and patent applications related to novel peptides and is currently sponsoring three Phase II chronic dermal wound healing clinical trials, a Phase II ophthalmic wound healing clinical trial, and a Phase IA parenteral ( injectable ) clinical trial supporting systemic delivery of RGN-352 for acute cardiovascular indications. RegeneRx Technology Background Tβ4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. It is a first-in-class multi-faceted molecule that promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition, and down-regulates inflammation. RegeneRx has identified several molecular variations of Tβ4 that may affect the aging of skin, among other properties, and could be important candidates as active ingredients in pharmaceutical and consumer products. Researchers at the National Institutes of Health, and at other academic institutions throughout the U. S. , have published numerous scientific articles indicating Tβ4's in vitro and in vivo efficacy in accelerating wound healing and tissue protection under a variety of conditions. Key publications related to Tβ4's cardio-protective effects have been published in Nature and Circulation. Abstracts of these and other scientific papers related to Tβ4's mechanisms of action may be viewed at RegeneRx's web page: http: //www. regenerx. com. Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Examples of such forward-looking statements include statements concerning the safety and efficacy of RGN-352, target dates for completing company's ongoing preclinical studies and clinical trials for dermal, ophthalmic, cardiovascular, neurovascular and orphan indications, potential size of addressable markets, including market for topical gels, sterile eye drops and parenteral delivery products, company's ability to enter into any collaborations with respect to development or commercialization of its product candidates, and the therapeutic potential of Tβ4 for dermal, ophthalmic, cardiovascular and neurovascular wounds. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include risk that although Tβ4 has demonstrated potential therapeutic benefit for dermal, ophthalmic, cardiovascular and neurovascular wounds, the company's product candidates may not demonstrate safety and/or efficacy in clinical trials, risk that encouraging results from early research, preclinical studies, compassionate use or clinical trials may not be confirmed upon further analysis of detailed results of such research, preclinical study, compassionate use or clinical trial, risk that additional information relating to safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, risk that company's or its collaborators won't obtain approval to market the company's product candidates in U. S. or abroad, risks associated with reliance on outside financing to meet capital requirements, risks associated with reliance on collaborators for funding or conduct of further development and commercialization activities relating to the company's product candidates, risks associated with protecting company's intellectual property, including risk that company won't be able to obtain patent protection or that its issued patents will be infringed, and such other risks described in the company's annual report on Form 10-K, for the year ended December 31, 2007, as amended, its quarterly report on Form 10-Q for period ended March 31, 2008, and other filings company makes with SEC. Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of date made. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Useful medical advises |
FDA's Strategic Plan: Charting Our Course for the Future. FDA's Strategic Action Plan sets forth the agency's longterm strategic goals and objectives. Pet Food Products Seized at PETCO Distribution Center. Consumers who bought animal food products from PETCO in 16 states should take certain precautions Civil Penalties Sought Against Maker of Hearing Aid. A hearing aid manufacturer breaks the law, and FDA is seeking more than $2 million in penalties Nexium Approved for Children 1 to 11 Years Old. Nexium, a drug that treats gastroesophageal reflux disease (GERD), has received FDA approval for short-term, low-dosage use in children ages 1 to 11 years old |
Red Tomato Warning Expanded Nationwide. The Food and Drug Administration is expanding its warning to consumers nationwide that a salmonellosis outbreak has been linked to consumption of certain raw red plum, red Roma, and red round tomatoes, and products containing these tomatoes. FDA 101: How to Use the Consumer Complaint System and MedWatch. When you have a problem with a food, drug, or other FDA-regulated product, FDA wants to hear from you. Here's how to report problems using two of FDA's main reporting systems. Your Guide to Reporting Problems to FDA. This guide provides tips and a quick-reference chart to help you report a problem to FDA. Warning for Regranex"Cream for Leg and Foot Ulcers. A boxed warning has been added to the label of Regranex Gel 0.01% to address the increased risk of cancer death in patients who use three or more tubes of the product. Stronger Warnings Requested for Fluoroquinolones. FDA has notified manufacturers of fluoroquinolones that a boxed warning on the increased risk of tendinitis and tendon rupture is necessary. Hard Exercise Curbs Metabolic Syndrome. Metabolic syndrome, which makes diabetes and heart disease more likely, may be curbed by aerobic interval training, a Norwegian study shows. 6 Steps to Longer Life, Healthy Heart. About 27 million heart attacks could be prevented over the next 30 years if U.S. adults met heart-health goals, researchers note. FDA Tests Cilantro, Peppers for Salmonella. The FDA is expanding its salmonella investigation by testing cilantro, jalapeno peppers, and Serrano peppers, as well as tomatoes, for Salmonella Saintpaul. Early Sex Doesn't Predict HPV Infection. Teenage girls who are sexually active and those who are not eventually all have the same risk for infection with the human papilloma virus, new research suggests. Baby’s Smile a Natural High for Mom. A new study shows seeing her baby's smile lights up the reward centers in a mother's brain. |
RegeneRx Completes Enrollment And Dosing Of Phase IA Safety Trial For Potential Heart Drug - First Injectable Use Of RGN-352 Tested In Humans Fluoxetine: useful modern medicine. FDA approved Fluoxetine FDA's Strategic Plan: Charting Our Course for the Future. FDA's Strategic Action Plan sets forth the agency's longterm strategic goals and objectives. Useful medical advises |